Here is a fact about cancer cell therapy that quietly explains why T-knife Therapeutics exists. The engineered T cells known as CAR-T have been near-miraculous against blood cancers - leukemias, lymphomas, the diseases that live in the bloodstream where a roaming immune cell can find them. Against solid tumors, the kind that form dense, hostile masses in the lung or ovary or throat, the same technology has mostly hit a wall. The tumor is a bad neighborhood. It tells incoming T cells to stop, to exhaust, to die. T-knife’s entire premise is that the fix is not more T cells but better receptors, and that the best way to find a better receptor is to not design it at all.
Instead, you grow it. T-knife was spun out of Berlin’s Max Delbrück Center in 2015, built on research from Professor Thomas Blankenstein, and its founding trick is a genetically humanized mouse - the HuTCR platform - that carries a full human T-cell receptor repertoire. Present that mouse with a human tumor antigen and its immune system does what immune systems do best: it selects, in vivo, for receptors with the right affinity and the right specificity. T-knife then harvests those fully human TCRs. The company is, in a sense, outsourcing the hardest part of drug design to evolution, which has a few billion years of experience.
This is a more radical idea than it sounds. Most of biotech spends enormous effort engineering affinity in a dish, tuning a receptor to bind a target harder. The risk is that a receptor tuned too hard starts binding things it shouldn’t - healthy tissue that happens to look a little like the tumor - which in cell therapy is the difference between a treatment and a catastrophe. By letting a mouse’s own selection process do the tuning, T-knife aims for receptors that are potent and discriminating, because nature already threw out the ones that weren’t.
The company has since built a second-generation engine it calls the MyT platform and moved its corporate center of gravity to San Francisco, though its research still runs out of Berlin. What it produces are what T-knife calls “supercharged” TCR-Ts: cells that don’t just target a tumor but are equipped to survive it. That distinction - targeting versus fitness - is the whole thesis, and it is why the science is worth understanding in detail.
